Adalimumab-afzb - Biologic Drug Details

Summary for adalimumab-afzb

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-afzb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-afzb Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-afzb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Adalimumab-afzb

Last updated: March 10, 2026

What is Adalimumab-afzb?

Adalimumab-afzb, marketed as AZELEX (brand name may vary by region), is a biosimilar to the originator biologic adalimumab (Humira). It received regulatory approval primarily in European markets, including Germany, and is indicated for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease.

Market Landscape for Adalimumab Biosimilars

Key Players and Competition

• Original Protein: Humira (AbbVie) with global sales exceeding $20 billion in 2022.[1]
• Approved Biosimilars: Several biosimilars target adalimumab, including Amgen’s Amjevita, Samsung Bioepis’ Hadlima, and Biocon/Bioeq’s Catzarya in various markets.
• Adalimumab-afzb: Approved in Europe in 2022; likely to enter markets such as Germany, Austria, and Italy initially.

Regulatory Status

• European Medicines Agency (EMA): Approved in 2022; highlights compliance with biosimilarity standards.
• U.S. Food and Drug Administration (FDA): Not yet approved as of 2023.
• Pricing and Reimbursement: Biosimilar entry generally leads to price reductions—average discounts range from 15-35% relative to the originator.[2]

Market Dynamics

Patent Expiry and Market Entry

• Humira’s Patent Expiry: Original patents expired in Europe in 2018 and in the U.S. in 2023, opening markets for biosimilars.
• Impact of Biosimilar Entry: Market share shifts occur rapidly; biosimilars capture approximately 30-50% of adalimumab prescriptions within three years of launch.[3]
• Adalimumab-afzb’s Entry Strategy: Focused on cost-competitive positioning in European healthcare systems willing to transition patients to biosimilars.

Adoption Factors

• Physician Acceptance: Influenced by biosimilarity data, interchangeability policies, and clinician confidence.
• Payer Reimbursement Policies: Favor biosimilars for cost savings; some countries implement incentives for prescribing biosimilars.
• Patient Acceptance: Generally high owing to similarities with the originator; some skepticism remains due to brand familiarity.

Pricing Trends

• Biosimilar prices in Europe often range 20-35% below originator prices.
• Discount levels have increased slightly over recent years, driven by competitive pressures.

Financial Trajectory

Revenue Projections

• Initial Launch (2022-2023): Limited revenue in Europe due to late market entry but potential for rapid growth.
• Long-term Growth: Driven by increased market penetration and expanding indications.

Year	Estimated Revenue (EUR millions)	Notes
2023	150-200	Early sales post-approval
2024	300-400	Growing adoption; expanded prescribing
2025	600-800	Broader uptake; potential entry into additional markets

Note: These figures depend on healthcare reimbursement policies, physician adoption rates, and competitive actions.

Cost Structure and Margins

• Manufacturing Costs: Biosimilars typically have higher production complexity but benefit from economies of scale as sales volume increases.
• Pricing Strategy: Generics and biosimilars usually operate with margin profiles of 25-35%, factoring in R&D amortization, manufacturing, and distribution costs.

Forecasting Risks and Opportunities

• Risks: Market resistance from originator companies, regulatory delays, supply chain disruptions, and policy shifts.
• Opportunities: Expansion into new therapeutic indications, geographic markets, and increased use in biosimilar substitution policies.

Policy and Market Trends Impacting Financial Outcomes

• Regulatory Environment: Favorable policies about biosimilar substitution and track-and-trace regulations improve market access.
• Market Consolidation: Mergers and collaborations among biosimilar manufacturers may influence pricing and supply dynamics.
• Global Rollout: As U.S. approval approaches, worldwide revenue potential increases substantially.

Summary Table: Key Market and Financial Indicators

Indicator	2022	2023	2024	2025
Market Approval (Europe)	Yes	N/A	N/A	N/A
Estimated Revenue (EUR)	N/A	150-200	300-400	600-800
Discount to Original (%)	20-35	20-35	20-35	20-35
Market Share (% of adalimumab)	0	5-10	15-20	25-30

Key Takeaways

• Adalimumab-afzb is positioned to capitalize on European biosimilar policies, though initial sales are modest.
• Market share growth depends heavily on physician uptake, payer reimbursement policies, and expiring patents of competitors.
• Revenue forecasts show a rapid increase from 2024 onward, aligned with broader biosimilar adoption.
• Competitive pressures are mounting with multiple biosimilars entering the market, which could compress margins.

FAQs

1. How does adalimumab-afzb compare price-wise to the originator?
It typically sells at a 20-35% discount relative to Humira in Europe.

2. What factors influence adoption rates of adalimumab-afzb?
Physician confidence, reimbursement policies, and patient acceptance.

3. When is adalimumab-afzb expected to enter the U.S. market?
No approval as of 2023; U.S. approval anticipated post-2023, possibly targeting 2024-2025.

4. How might biosimilar competition affect adalimumab-afzb’s revenue?
Intense competition can reduce prices and market share, impacting total revenue.

5. What indications does adalimumab-afzb target?
Autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease.

References

[1] Statista. (2023). Humira’s global sales in 2022.
[2] IMS Health. (2022). Biosimilar pricing trends in Europe.
[3] IQVIA. (2022). Biosimilar market penetration data.